Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13720758 | 0.91 | ALDH1A1 (0.41) | POLBMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL13720760 | 0.91 | ALDH1A1 (0.41) | POLBMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL13721374 | 0.88 | ALDH1A1 (0.40) | POLBMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL13721375 | 0.88 | ALDH1A1 (0.40) | POLBMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL13721377 | 0.88 | ALDH1A1 (0.40) | POLBMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL13720980 | 0.88 | HPGD (0.40) | POLBMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL13720799 | 0.86 | ALDH1A1 (0.50) | POLBMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL1791096 | 0.85 | HPGD (0.41) | MEN1KMT2AHPGDALDH1A1RAB9A | |
| SCHEMBL1791097 | 0.85 | HPGD (0.41) | MEN1KMT2AHPGDALDH1A1RAB9A | |
| SCHEMBL13720461 | 0.85 | LMNA (0.40) | MEN1KMT2AHPGDALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859549-B2 | Potassium channel modulators | ABBVIE, INC. (US) | 2014-10-14 | — | — | US | claimed |
| US-20120289500-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-11-15 | — | — | US | claimed |
| US-8859549-B2 | Potassium channel modulators | ABBVIE, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| WO-2012158399-A1 | CONDENSED 2 - CARBAMOYLPYRIDAZINONES AS POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-11-22 | — | — | WO | disclosed |
| US-20120289500-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289500-A1 | POTASSIUM CHANNEL MODULATORS | KCNQ1, KCNQ2, KCNJ2 | POLB 4320/4885MEN1 1274/4885KMT2A 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.